InvestorsHub Logo
Followers 2
Posts 116
Boards Moderated 0
Alias Born 11/23/2020

Re: None

Tuesday, 02/09/2021 4:29:50 PM

Tuesday, February 09, 2021 4:29:50 PM

Post# of 36585
"It is estimated that over 200 patients will have completed the study for the interim analysis by the end of the second quarter of 2021. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option"